Health
Melanoma Patients Get New Hope as Personalised mRNA Vaccine Cuts Risk by 42%
Merck and Moderna have released late-stage trial results for their personalised melanoma vaccine, showing a 42 percent cut in the risk of death or recurrence.
Health
Health news from Trending News Talk: medical findings, public health and wellbeing, reported carefully and clearly.
